Portolan Capital Management’s Telix Pharmaceuticals TLX Stock Holding History

Portolan Capital Management’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.18M	Buy	+541,267	New	+$4.12M	0.28%	96

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

RBI

Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Portolan Capital Management's TLX Position: Q1 2026 in Review

Portolan Capital Management opened a new position in Telix Pharmaceuticals (TLX) in Q1 2026: 541,267 shares worth $5.18M. The stake represents 0.28% of the portfolio and ranks #96 among its holdings.

39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

Portolan Capital Management held 541,267 shares of Telix Pharmaceuticals worth $5.18M as of Q1 2026.
Telix Pharmaceuticals was a new Portolan Capital Management position in Q1 2026.
Telix Pharmaceuticals made up 0.28% of Portolan Capital Management's portfolio in Q1 2026, its #96 holding.
39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.